Good Distribution Practices (GDP) for Active Pharmaceutical Ingredients (APIs) represents a systemic solution, aimed at ensuring the safety of medicines throughout the entire supply chain. These changes, are part of the Eurasian Economic Integration Development Strategy 2025, aimed at creating a unified approach for pharmaceuticals within the Eurasian Economic Union. This will establish new requirements for market participants and open up opportunities for professional logistics operators capable of ensuring full compliance with international quality standards.
The Good Distribution Practices system goes beyond recommendations and becomes a mandatory condition for legal activity for importers and distributors of APIs.
The Good Distribution Practices system goes beyond recommendations and becomes a mandatory condition for legal activity for importers and distributors of APIs.
Key changes for Active Pharmaceutical Substances participants
1. Mandatory registration and GDP compliance
Importers and distributors of active ingredients intended for medicinal product manufacturing in EAEU countries are required to register with the authorized national body and comply with the GDP principles for pharmaceutical substances. This is a direct requirement, making GDP compliance not only a recommendation, but a mandatory condition for legal operation.
2. Strengthening control over the entire supply chain
GDP requirements apply not only to warehousing, but to all logistics operations, including transportation. This means companies must ensure:
- Maintaining prescribed storage conditions (especially temperature conditions) throughout the entire transportation period.
- Protecting products from contamination by other substances and cross-contamination.
- Adequate traceability at all stages of the movement of the active pharmaceutical substance.
3. Implementation of a tracking system and recall procedures
Distributors are required to implement an effective tracing system that enables the prompt identification of defective product batches and a well-established procedure for recalling such products from the market. This is critical for quickly responding to potential threats to patient health.
4. Increased requirements for personnel and documentation
Responsible Person. Their activities, even if carried out remotely, must, as a general rule, be conducted within the jurisdiction of the EAEU. Furthermore, as international experience shows, language proficiency requirements for Responsible Persons are being tightened, which is relevant for the multilingual nature of the EAEU.
WELLGO: A Strategic Partner in the Context of New GDP Requirements
The transportation and storage of APIs are considered critical stages in the supply chain from manufacturer to end user. This mandates requirements such as audits, quality agreements, documented suitability for use, and regular re-assessments.
At WELLGO, we recognize the strategic importance of GDP compliance for pharmaceutical companies. Our pharmaceutical logistics vertical operates in full compliance with Good Distribution Practices, as confirmed by annual audits of leading pharmaceutical manufacturers and the possession of valid GDP Compliance Certificates.
At WELLGO, we recognize the strategic importance of GDP compliance for pharmaceutical companies. Our pharmaceutical logistics vertical operates in full compliance with Good Distribution Practices, as confirmed by annual audits of leading pharmaceutical manufacturers and the possession of valid GDP Compliance Certificates.
Our competitive advantages in the face of the new requirements are demonstrable:
- Global expertise with a focus on Asia: Our direct partnerships with suppliers in India and China, the world's leading API producers, ensure supply chain optimization and reduced delivery times.
- Technological quality control: Continuous monitoring of transportation and storage conditions for temperature-sensitive goods. Using modern tracking systems ensures product quality is maintained at all stages.
- Comprehensive customs support: Our professional clearance of pharmaceutical substances, state-of-the-art pharmaceutical products, pharmaceutical equipment, and reagents. In accordance with EAEU requirements, this minimizes the risk of delays and compromised supply chain integrity.
- Personalized approach: Our team, with deep expertise in pharmaceutical logistics, develops sustainable solutions tailored to each client's specific needs and regulatory requirements.
In the face of increasingly stringent GDP requirements, choosing a partner capable of not only providing physical delivery but also guaranteeing full compliance with international Quality Standards is becoming a strategic decision for your business.
Contact WELLGO today for a consultation on optimizing your pharmaceutical supply chain! Our experts will analyze your current logistics processes, identify potential risks of GDP compliance, and offer a customized solution to ensure product quality and uninterrupted supply amid the transformation of the EAEU market.
WELLGO is your reliable partner in a world where responsibility and care for every cargo is not just a slogan, but a system of guaranteed results and an indicator of business sustainability.
Contact WELLGO today for a consultation on optimizing your pharmaceutical supply chain! Our experts will analyze your current logistics processes, identify potential risks of GDP compliance, and offer a customized solution to ensure product quality and uninterrupted supply amid the transformation of the EAEU market.
WELLGO is your reliable partner in a world where responsibility and care for every cargo is not just a slogan, but a system of guaranteed results and an indicator of business sustainability.